Phase II study of bemnifosbuvir in high-risk participants in a hospital setting with moderate COVID-19.

Phase II study of bemnifosbuvir in high-risk participants in a hospital setting with moderate COVID-19.

Horga, Arantxa; Kuritzkes, Daniel R; Kowalczyk, John J; Pietropaolo, Keith; Belanger, Bruce; Lin, Kai; Perkins, Kristen; Hammond, Janet.

Horga A; Atea Pharmaceuticals, Boston, MA 02110, USA.
Kuritzkes DR; Brigham & Women's Hospital, Division of Infectious Disease, Boston, MA 02115, USA.
Kowalczyk JJ; American Institute of Research, Los Angeles, CA 90017, USA.
Pietropaolo K; Atea Pharmaceuticals, Boston, MA 02110, USA.
Belanger B; Atea Pharmaceuticals, Boston, MA 02110, USA.
Lin K; Atea Pharmaceuticals, Boston, MA 02110, USA.
Perkins K; Atea Pharmaceuticals, Boston, MA 02110, USA.
Hammond J; Atea Pharmaceuticals, Boston, MA 02110, USA.

Future Virol ; 18(8): 489-500, 2023 Jun.

Article en En | MEDLINE | ID: mdl-38051993